BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Research Pipeline · 30 Oct 2026
Retatrutide Beats Semaglutide 2 mg on Every Primary Endpoint in First Phase 3 Head-to-Head Trial: What the TRANSCEND-T2D-2 Results Mean for Research Procurement
Eli Lilly's triple GIP/GLP-1/glucagon receptor agonist retatrutide produced more than double the weight loss of Ozempic's highest approved dose at 80 weeks in adults with type 2 diabetes, according to topline Phase 3 TRANSCEND-T2D-2 data released on 28 October 2026. The readout — the sixth consecutive positive Phase 3 trial for the compound — solidifies retatrutide's clinical profile and accelerates the timeline toward a potential regulatory filing, with direct implications for how research…
Read briefing →
Regulatory & Policy
HHS Issues Enforcement Discretion Policy for Six Peptides: What the 28 October Announcement Means for Research Procurement
The US Department of Health and Human Services announced on 28 October 2026 that it will not pursue enforcement action against state-licensed 503A compounding pharmacies that compound BPC-157, Epitalon, KPV, MOTS-c, Semax, or TB-500, provided strict quality and reporting conditions are met. The policy does not constitute FDA approval, does not extend to research-use-only channels, and may be withdrawn at any time — distinctions that UK research-procurement teams must keep firmly in view.
29 Oct 2026
Research Pipeline
MOTS-c: What the July 2026 PCAC Vote and the October Interim Policy Mean for Research Procurement
The FDA's Pharmacy Compounding Advisory Committee voted 7–5 in July 2026 to recommend MOTS-c for the 503A Bulks List, overruling its own staff. Three months on, formal rulemaking has not begun and MOTS-c remains unlisted. This briefing sets out what MOTS-c is, where the evidence stands, and what the unresolved regulatory picture means for UK research procurement.
28 Oct 2026
Industry & Community
No Road Back for Large-Scale GLP-1 Compounding: What the Closing 503B Pathway and Chinese API Scandal Mean for Research Procurement
The FDA's proposal to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk compounding list — combined with FOIA-obtained inspection reports documenting contamination and falsified records at two Chinese API suppliers — signals that the legal and supply-chain foundations of large-scale GLP-1 compounding have effectively collapsed. UK research procurement teams that source these peptides should understand what remains lawful, what does not, and where the supply risks…
27 Oct 2026
Pharma & GLP-1
Gilead Pays $1.275 Billion for an Oral Macrocyclic Peptide: What the PepStar Deal Signals for the Next Wave of Peptide Drug Development
Gilead Sciences agreed on 22 October 2026 to acquire PepStar Therapeutics' oral IL-23R inhibitor programme, led by macrocyclic peptide HCXT-2001, for $1.275 billion upfront. The deal is the latest evidence that big pharma's appetite for oral peptide formats extends well beyond the GLP-1 obesity category into immunology and inflammatory bowel disease.
26 Oct 2026
Regulatory & Policy
Safety Group Challenges PCAC Integrity as Peptide Access Policy Sits at the White House: What the PSM Citizen Petition Means for the Regulatory Outlook
The Partnership for Safe Medicines has filed a formal citizen petition asking the FDA to block compounding of seven peptides — including BPC-157, TB-500 and Epitalon — and to disregard the July PCAC advisory vote as tainted by conflicts of interest. The petition lands while the agency's interim access policy remains under White House review, deepening the regulatory uncertainty facing research procurement teams.
25 Oct 2026
Pharma & GLP-1
Novo Nordisk Bets €1.165 Billion on Atomic Layer Deposition: What the Nanexa PharmaShell Deal Means for Long-Acting Peptide Formulation
Novo Nordisk has licensed Swedish delivery specialist Nanexa's PharmaShell atomic layer deposition platform for up to five peptide programmes targeting obesity and cardiometabolic disease, with monthly and quarterly dosing as target profiles. The deal, worth up to €1.165 billion, signals that the GLP-1 leaders view reduced injection frequency — not simply new molecules — as a critical next competitive frontier.
24 Oct 2026
Reputational Risks
Filthy Warehouse, 12,000 Counterfeit Pens, and a Clinic Inquiry: What the MHRA's October Enforcement Blitz Means for UK Research Procurement
A joint MHRA and West Midlands Police raid on 14 October seized more than 12,000 counterfeit retatrutide and tirzepatide pens — worth an estimated £2 million — from a Birmingham industrial unit. Paired with an ongoing MHRA inquiry into private clinics making unsubstantiated peptide claims, the month illustrates how UK enforcement against illicit GLP-1 and research-peptide supply chains is escalating well beyond symbolic warnings.
23 Oct 2026
Research Pipeline
Beyond the GLP-1 Duopoly: Three October Developments That Signal a Broadening Obesity Pipeline
A Phase 2b trial win for Zealand Pharma's amylin analogue petrelintide, a £1.2 billion AI-protein partnership with Generate Biomedicines, and Novo Nordisk's €1.165 billion bet on long-acting PharmaShell technology collectively point to an obesity therapeutics landscape that is moving deliberately beyond weekly GLP-1 injections.
22 Oct 2026
Reputational Risks
Two Deaths, Eleven Lawsuits, and a Congressional Letter: The Mounting Enforcement Response to Illicit Retatrutide
The illicit market for retatrutide — an experimental triple-receptor agonist still in clinical trials — has reached a new threshold of harm. Two adverse-event deaths have been reported to the FDA, Eli Lilly has now filed eleven lawsuits against black-market sellers, and a bipartisan group of lawmakers wrote to the FDA on 20 October urging closure of the importation loophole. Research procurement teams sourcing investigational peptides need to understand the legal and safety signals this…
21 Oct 2026
Reputational Risks
Sterility Failure at a Forewarned Compounder: What the Apothecary Pharma Tirzepatide Recall Reveals About Persistent Quality Gaps
The FDA has classified a nationwide recall of 22 compounded tirzepatide vials from Apothecary Pharma LLC as a Class II action, citing a lack of sterility assurance — nearly a year after issuing the same pharmacy a warning letter for identical deficiencies. The case illustrates how prior regulatory notice has not prevented sterility failures from recurring in the compounded GLP-1 sector.
20 Oct 2026
Regulatory & Policy
Peptide Interim Access Policy Enters White House Review: What the OIRA Submission and This Week's OMB Meeting Mean for Research Procurement
FDA and HHS formally submitted an "Interim Access Policy for Compounding Using Certain Peptides" to the White House Office of Information and Regulatory Affairs on 14 October 2026. With the American Academy of Peptide Medicine scheduled to meet the Office of Management and Budget on 22 October, the policy has moved from internal deliberation into active White House scrutiny — though its substance, scope and timing remain publicly undisclosed.
19 Oct 2026